4G·

Novo Nordisk - is it worth getting in? What do you think

📊 Fundamental key figures

Turnover 2024DKK 290.4 billion (+26% compared to the previous year)
EBITDA margin 2024approx. 51 %
Forecast for 2025: Revenue growth in the low double-digit range, which is below the previous year's level

Analysts expect earnings per share to average DKK 26.91 in 2025, which corresponds to an increase of around 18.7

🧪 Product pipeline and competition

Novo Nordisk remains the leader in diabetes and obesity with established products such as Ozempic and Wegovy. However, Eli Lilly is gaining market share with Zepbound and Mounjaro. The disappointing study results for CagriSema increase the pressure on Novo Nordisk to strengthen its product pipeline.

📈 Analyst opinions and price targets

Analysts' opinions are mixed. Some recommend buying the share, while others advise caution. The price targets for 2025 vary between DKK 473 and DKK 540, which implies a moderate upside potential of up to 15% compared to the current price.

🧭 Conclusion

In the medium term, Novo Nordisk remains a solid company with strong fundamentals and a leading position in diabetes. However, increasing competition in the obesity market, disappointing trial results and regulatory uncertainties weigh on the short-term outlook. For risk-conscious investors with a long-term horizon, the current valuation could nevertheless be attractive.

32 Commenti

Sebi@Seebi

A very clear NO, and my condolences to all those who have recently invested. I hope with you🙏

•

Jan H.@J4nh44g

@Seebi I hope that all those who have bought in will now hope and believe even more strongly.

••

StockAddict@StockAddict

So anyone who invests money and "hopes and believes" should rather play bingo. Novo Nordisk is fundamentally one of the best companies in Europe.

•

Sebi@Seebi

@J4nh44g they are just buying up, from next week when it goes down again they hope and believe again

••

PaulPK@PaulPK

@StockAddict That is the status quo - but they are losing market share...

••

Epi@Epi

@Seebi You have forgotten love, my dear! The love! 😢

"But now faith, hope and love remain, these three; but love is the greatest of these." (1 Cor 13:1ff

•

Sebi@Seebi

@StockAddict I say that to Novo investors every day. They'd better play bingo

••

Sebi@Seebi

@Epi are you getting romantic 😀

••

Pedi@Pedi

@Seebi What made you say a clear 'no'? The green from the creator post?

••

Olli@Olli68

@StockAddict And the market doesn't know it yet?

••

Epi@Epi

@Seebi Not really. I'm not talking about romantic love. 😁

•

Visualizza tutti 5 ulteriori risposte

K K.@userb0ca8bbd97d44646

So I don't understand some investors - at €120.00 it was the top share par excellence, at €52.00 nobody wants it. What has changed fundamentally? Still the global market leader in diabetes, highly profitable and growing. Only the extreme hype caused by obesity has faded. I'm continuing to stock up, even if the withholding tax is really annoying...

•

Artiskon@Artiskon

You can't ask about Novo here - the millionaire profit traders want profits today, not tomorrow, so it's not interesting for this community.

•

Uwe@SchlaubiSchlumpf

From everything I've read now, they also sound fundamentally solid.
More like a long runner. Probably also have to watch out for competition and distortion. But it should be an acceptable risk. If I'm assessing this correctly as a layman, they are probably back at fair value at the moment after being traded too high for a long time. If they fall even more, they could probably be a buy depending on the economic situation, right? 🤔 (okay not for me, I only buy ETFs and REITs, but in general)

•

Tino@parlania

If things don't go down for a month, then perhaps yes....

•

Olli@Olli68

Nein.

••

SakEr@SakEr

Since I haven't been around that long, maybe a stupid question, but why buy the stock when it has been going down for a year and has lost a little more than 54%?

••

Patrick Schäfer@Hotte1909

@SakEr um es in Bonnie Tylers Worte zu fassen
(Turn around)
Every now and then, I get a little bit lonely
When you're never comin′ 'round
(Turn around) thank you
Every now and then, I get a little bit tired
Of listening to the sound of my tears

(Turn around) thank you
Every now and then, I get a little bit nervous
That the best of all the years have gone by
(Turn around) ha
Every now and then, I get a little bit terrified
And then I see the look in your eyes

•

SakEr@SakEr

@Hotte1909 beautiful song by Bonnie Tyler :)

••

Patrick Schäfer@Hotte1909

@SakEr 😀

••

Investor18@Investor18

@SakEr In general, the risk of a share that has not changed fundamentally is lower if the price falls. The price fluctuation is then influenced by "Mr. Market" (according to Graham).
Now Novo is rock solid and a loss of 54 percent can therefore make a share attractive. But if you're new to this, I'd recommend you stay away from shares and put everything into an ETF. That way you will beat 90 percent of the stock pickers

••

Gomerdoc@Gomerdoc

@SakEr e.g. because you've had shares since 1998 and can't stop laughing 😉....

•

MarTheRadi@marda304

Perfect fir tree chart

••

Michael K.@AlexisMachine

Next come the Medi tariffs. It will probably go down again straight away.

••

Thomas@waldbrandgefahr

Trump still wants to announce pharma tariffs. The competition to $NOVO B never sleeps. The monopoly position is being lost. I fear that anyone who invests now will pay the price

••

PaulPK@PaulPK

Novo Nordisk could be affected in the short term by possible US tariffs on pharmaceutical imports. The US government under President Trump is planning to impose tariffs on pharmaceutical products from Europe, which would directly affect companies like Novo Nordisk. These measures could lead to higher prices for drugs such as Wegovy and Ozempic and put pressure on the company's profit margins.

Despite these challenges, Novo Nordisk is confident. CEO Lars Fruergaard Jørgensen emphasized that the company is well positioned to meet the requirements of the US administration. Novo Nordisk is also investing heavily in expanding its production capacity in the US, particularly in North Carolina, to minimize potential customs burdens and ensure supply to the US market.
The Guardian
+1
Reuters
+1

In the long term, these investments could help to mitigate the impact of tariffs. However, there is a short-term risk of supply delays and price increases, especially if tariffs are introduced quickly and without transition periods. The situation remains volatile, and market reactions and possible countermeasures by the EU could bring additional uncertainty.

Overall, Novo Nordisk is not immune to the effects of tariffs, but is well equipped to meet these challenges thanks to strategic investments and a strong market position.

••

Heiko G.@Ozzel

I'll continue to go in with a savings plan, 50 euros a month, I think it will pay off in the long term.

As I already wrote in another post:

The price drop is not fundamentally based, but rather technical in nature (overvaluation + chart correction).
Tariffs? Not a real risk factor.
Dividend? Solidly covered - and even countercyclically attractive if the decline continues.

If you believe in GLP-1 as a long-term megatrend (obesity, type 2 diabetes, prevention), Novo Nordisk is still a top pick in the healthcare sector

••